Revumenib is a first-in-class oral menin inhibitor used to treat relapsed or refractory acute leukemia with KMT2A rearrangements (KMT2Ar).
Revumenib
Generic Name/API:Revumenib
Storage:Store Revumenib at room temperature between 68°F to 77°F (20°C to 25°C).
Dosage:For dosage information, please visit the General Information section.
Strength:Tablets of strengths 25 mg, 110 mg, 160 mg
Indication:Revumenib is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation as determined by an FDA-authorized test in adult and pediatric patients 1 year and older; the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
Revumenib, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements. It is intended to interfere with menin’s interaction with KMT2A, or MLL, which is involved in the pathophysiology of these leukemias. Revumenib was approved for medical use in the United States in November 2024.
Revumenib is a first-in-class oral menin inhibitor that treats acute leukemia with KMT2A (MLL) rearrangements or NPM1 mutations. It functions by preventing menin from interacting with the KMT2A protein, which is a major cause of aberrant gene expression in these leukemias. By suppressing the expression of leukemia-promoting genes like HOXA9 and MEIS1, this inhibition lowers the burden of leukemia by enabling immature leukemic blast cells to cease multiplying and develop into normal blood cells.
Strength:
Tablets of strengths 25 mg, 110 mg, 160 mg
Dosage:
Administer Revumenib orally twice daily fasted or with a low-fat meal at approximately the same time each day.
Recommended Dosage for Patients 1 Year and Older:
| Patient Weight | Without Strong CYP3A4 Inhibitors | With Strong CYP3A4 Inhibitors |
| 40 kg or more | 270 mg orally twice daily | 160 mg orally twice daily |
| Less than 40 kg | 160 mg/m² orally twice daily* | 95 mg/m² orally twice daily* |
Recommended Dosage using Tablets* for Patients Weighing Less than 40 kg:
| BSA (m²) | Dosage for 160 mg/m² | Dosage for 95 mg/m² |
| 1.4 | 220 mg twice daily | 135 mg twice daily |
| 1.3 | 220 mg twice daily | 135 mg twice daily |
| 1.2 | 185 mg twice daily | 110 mg twice daily |
| 1.1 | 185 mg twice daily | 110 mg twice daily |
| 1 | 160 mg twice daily | 100 mg twice daily |
| 0.9 | 135 mg twice daily | 75 mg twice daily |
| 0.8 | 135 mg twice daily | 75 mg twice daily |
| 0.7 | 110 mg twice daily | 50 mg twice daily |
| 0.6 | 100 mg twice daily | 50 mg twice daily |
| 0.5 | 75 mg twice daily | 50 mg twice daily |
| 0.4 | 50 mg twice daily | 25 mg twice daily |
ADVERSE REACTIONS:
The most common adverse reactions (≥ 20%) including laboratory abnormalities, are phosphate increased, hemorrhage, nausea, infection without identified pathogen, aspartate aminotransferase increased, alanine aminotransferase increased, creatinine increased, musculoskeletal pain, febrile neutropenia, electrocardiogram QT prolonged, potassium decreased, parathyroid hormone intact increased, alkaline phosphatase increased, diarrhea, bacterial infection, triglycerides increased, differentiation syndrome, fatigue, edema, viral infection, phosphate decreased, decreased appetite, and constipation.
Storage:
Store Revumenib at room temperature between 68°F to 77°F (20°C to 25°C).
- Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of potential risk to a fetus and to use effective contraception
- Revumenibcan cause fatal or life-threatening differentiation syndrome (DS). Symptoms of differentiation syndrome, including those seen in patients treated with REVUFORJ, include fever, dyspnea, hypoxia, peripheral edema, pleuropericardial effusion, acute renal failure, rash, and/or hypotension.
- QTc Interval Prolongation and Torsades de Pointes
FAQ
How does Revumenib work?
It blocks the interaction between menin and KMT2A, reducing the expression of leukemia-driving genes (such as HOXA9 and MEIS1) and allowing leukemic cells to mature into normal blood cells.
How is Revumenib administered?
It is an oral tablet taken twice daily in 28-day treatment cycles.
What are the common side effects of Revumenib?
Common adverse effects include nausea, vomiting, diarrhea, constipation, fatigue, edema, abdominal pain, musculoskeletal pain and QT interval prolongation.
What is the cost of Revumenib (Revuforj) in India?
The Revumenib price in India varies, as access to the medication in India requires importation. Changes in exchange rates and applicable import duties can affect the final cost. For current pricing and availability, contact 24/7QualityMeds at +91 9967979080 .
How to buy Revumenib (Revuforj) online in India?
To buy Revumenib in India online at a genuine price, contact 24/7 QualityMeds. We will assist you with accessing this medication through a compliant import process and help coordinate its delivery to you in India securely and reliably.
How to buy Revumenib (Revuforj) in Delhi?
To buy Revumenib (Revuforj) in Delhi, contact 24/7QualityMeds for assistance with your Revumenib request. Our team will guide you through import documentation and coordinate the medication’s delivery to your location in Delhi.
